Remote ischemic conditioning

Acticor Biotech Announces the Success of the First Phase of its ACTIMIS study with Glenzocimab In Patients with Acute Ischemic Stroke

Retrieved on: 
Thursday, October 1, 2020
Health, Other Health, Other Science, Clinical trials, Research, Science, Biotechnology, Medical specialties, RTT, Stroke, Thrombosis, Ischemia, Clinical medicine, Medicine, Chloroarenes, Tissue plasminogen activator, Remote ischemic conditioning, glenzocimab (ACT017), the Therapeutic Candidate, Acticor Biotech

Acticor Biotech, a clinical stage biotechnology company involved in the acute phase of thrombotic diseases, including acute ischemic stroke, today announced the completion of its ACTIMIS Dose Escalation Phase of Glenzocimab Study as add-on to standard of care in Patients with acute ischemic stroke.

Key Points: 
  • Acticor Biotech, a clinical stage biotechnology company involved in the acute phase of thrombotic diseases, including acute ischemic stroke, today announced the completion of its ACTIMIS Dose Escalation Phase of Glenzocimab Study as add-on to standard of care in Patients with acute ischemic stroke.
  • This Dose Escalation Phase was successfully completed with 60 patients enrolled from 6 European countries (France, Belgium, Germany, Spain, Switzerland and Italy).
  • This is an important milestone for the company and an important progress in the emergency treatments of ischemic stroke.
  • Acticor Biotech is a clinical stage biotechnology company, spin-off of INSERM, dedicated to developing an innovative treatment in the therapy of acute thrombotic diseases, including ischemic stroke.

CalciMedica Announces Positive Topline Data from Interim Analysis of Trial Evaluating Auxora™ in Patients with Severe COVID-19 Pneumonia

Retrieved on: 
Thursday, May 28, 2020
Medicine, Clinical medicine, Medical specialties, Respiratory therapy, Medical ventilator, Hepatology, Medical equipment, Intensive care medicine, Remote ischemic conditioning, Tuberculosis management

The interim analysis showed Auxora plus standard of care reduced ventilator use and improved time to recovery in treated patients compared to standard of care alone.

Key Points: 
  • The interim analysis showed Auxora plus standard of care reduced ventilator use and improved time to recovery in treated patients compared to standard of care alone.
  • The open-label study consists of 26 patients enrolled while on low-flow oxygen and randomized 2:1 to receive Auxora versus standard of care.
  • The interim analysis showed that treated patients had a greater than 50% reduction in the proportion of patients put on ventilators in the course of therapy as compared to standard of care patients.
  • Additionally, the length of hospital stay for Auxora treated patients was more than 50% shorter than for standard of care patients.

Health System in Pandemic Epicenter Identifies Outcomes and New Risk Factors of Patients Hospitalized with COVID-19

Retrieved on: 
Tuesday, May 26, 2020
Branches of biology, Animal physiology, Human physiology, Immunology, Inflammation, Remote ischemic conditioning

We also showed that the degree of oxygen impairment and markers of inflammation in patients were most strongly associated with poor outcomes during hospitalization."

Key Points: 
  • We also showed that the degree of oxygen impairment and markers of inflammation in patients were most strongly associated with poor outcomes during hospitalization."
  • As a result, Horwitz says clinicians should routinely test COVID-19 patients for inflammatory markers throughout their hospitalization.
  • The strongest risk for hospitalization was age (40 percentage points increased risk for patients 65-74, and 58 percentage points increased risk for patients 75 years or older).
  • Similarly, having chronic diseases increases risk, but one in five of our hospitalized patients had no chronic conditions."

electroCore Submits Emergency Use Authorization Application to Allow the Study and Use of gammaCore nVNS Therapy to Treat Respiratory Symptoms Associated with COVID-19

Retrieved on: 
Thursday, April 2, 2020
Drugs, GABAA receptor positive allosteric modulators, RTT, Psychoactive drugs, Carbamates, Remote ischemic conditioning, Benzodiazepine

These studies suggest a possible benefit for patients with respiratory distress associated with COVID-19.

Key Points: 
  • These studies suggest a possible benefit for patients with respiratory distress associated with COVID-19.
  • Additionally, gammaCores strong safety and tolerability profile suggest that it would be safe to study or use in patients with COVID-19.
  • It should also be noted that to date no randomized clinical trials have been performed utilizing gammaCore in patients with COVID-19.
  • Designed as a portable, easy-to-use technology, gammaCore can be self-administered by patients, as needed, without the potential side effects associated with commonly prescribed drugs.

Global Chronic Coronary Artery Disease - Clinical Trials Review, H1, 2020 - ResearchAndMarkets.com

Retrieved on: 
Friday, March 13, 2020
Health, Cardiology, RTT, Health, Circulatory system, Branches of biology, Coronary artery disease, Coronary arteries, Cardiovascular disease, Clinical trial, Heart, Remote ischemic conditioning, TIMI

The "Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) Global Clinical Trials Review, H1, 2020" clinical trials has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) Global Clinical Trials Review, H1, 2020" clinical trials has been added to ResearchAndMarkets.com's offering.
  • This clinical trial report, Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) Global Clinical Trials Review, H1, 2020" provides an overview of Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease) Clinical trials scenario.
  • This report provides top line data relating to the clinical trials on Chronic Coronary Artery Disease (CAD) (Ischemic Heart Disease).
  • The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type.

NeuroVive Completes Recruitment in the Second Part of its Ongoing KL1333 Clinical Phase Ia/b Study

Retrieved on: 
Friday, December 20, 2019
Neurotrauma, Medical specialties, Medicine, Health, Neurological disorders, Intensive care medicine, Psychiatric diagnosis, Traumatic brain injury, Brain damage, Remote ischemic conditioning, Center for BrainHealth

After evaluation of results from the two first parts of the study, the third and final part will be initiated.

Key Points: 
  • After evaluation of results from the two first parts of the study, the third and final part will be initiated.
  • In this part, repeated doses of KL1333 will be given to patients with primary mitochondrial disease.
  • The focus of the ongoing study, conducted in the UK, is to evaluate safety and pharmacokinetics of KL1333.
  • NeuroSTAT for traumatic brain injury (TBI) is ready to enter a clinical phase II efficacy study.

Large Randomized Controlled Trial Aims to Curb Rising Epidemic of Heart Failure

Retrieved on: 
Monday, December 16, 2019
Medical Supplies, Health, FDA, Practice Management, General Health, Clinical trials, Cardiology, Medicine, Circulatory system, Cardiovascular system, Medical emergencies, Interventional cardiology, Medical devices, Cardiology, Aging-associated diseases, Impella, Percutaneous coronary intervention, Myocardial infarction, Remote ischemic conditioning

View the full release here: https://www.businesswire.com/news/home/20191216005331/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20191216005331/en/
    The STEMI DTU randomized controlled trial will study unloading with the FDA approved Impella heart pump as a therapy to reduce heart failure risk.
  • (Photo: Business Wire)
    With the aging population and rising rates of heart failure, the research being conducted in this trial has the potential to be far reaching and meaningful.
  • Patients with large anterior myocardial infarction continue to have unacceptably high rates of death and heart failure despite successful primary PCI.
  • The multi-center, two-arm randomized controlled trial (RCT) plans to enroll 668 patients undergoing treatment for a STEMI heart attack.

Late-Breaking KIDNEY Clinical Trial Results: RenalGuard Therapy Prevents Acute Kidney Injury After Cardiac Surgery

Retrieved on: 
Thursday, November 7, 2019
Kidney diseases, Medical specialties, Medicine, Anatomy, Acute kidney injury, Contrast-induced nephropathy, Kidney disease, Nephrology, Kidney, Renal angina, Remote ischemic conditioning

MILFORD, Mass., Nov. 7, 2019 /PRNewswire/ -- RenalGuard Solutions , a pioneering medical device company focused on protecting patients from acute kidney injury (AKI), announced today that the KIDNEY clinical trial confirmed RenalGuard Therapy better protects at-risk patients undergoing cardiac surgery with cardiopulmonary bypass (CPB) from Acute Kidney Injury (AKI).Results of the 220 patient, randomized trial comparing automated diuresis technology to standard hydration were presented at the American Society of Nephrology's Kidney Week meeting held in Washington D.C., Nov. 5-10, 2019.

Key Points: 
  • MILFORD, Mass., Nov. 7, 2019 /PRNewswire/ -- RenalGuard Solutions , a pioneering medical device company focused on protecting patients from acute kidney injury (AKI), announced today that the KIDNEY clinical trial confirmed RenalGuard Therapy better protects at-risk patients undergoing cardiac surgery with cardiopulmonary bypass (CPB) from Acute Kidney Injury (AKI).Results of the 220 patient, randomized trial comparing automated diuresis technology to standard hydration were presented at the American Society of Nephrology's Kidney Week meeting held in Washington D.C., Nov. 5-10, 2019.
  • "The KIDNEY trial adds to a growing body of clinical evidence showing that RenalGuard Therapy is a very effective means of preventing acute kidney injury in at-risk patients," said Dr. Howard Levin, RenalGuard Solutions' Chief Medical Officer.
  • "Last month, a 700+-patient, multi-center, randomized clinical trial found RenalGuard to be superior to the POSEIDON protocol in preventing contrast-induced AKI."
  • The company's RenalGuard Therapy is designed to prevent surgery- or procedure-induced acute kidney injury (AKI), as well as contrast-induced nephropathy (CIN) for at-risk patients undergoing interventional procedures using contrast.

Global Acute Myocardial Infarction Clinical Trial Pipeline Highlights, 2019 - ResearchAndMarkets.com

Retrieved on: 
Monday, June 10, 2019
Health, Cardiology, Clinical trials, Pharmaceutical, Health, Clinical research, Design of experiments, Medicine, Clinical pharmacology, Clinical trial, Drug discovery, Pharmaceutical industry, Remote ischemic conditioning, Trevena Inc

The "Global Acute Myocardial Infarction Clinical Trial Pipeline Highlights, 2019" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Acute Myocardial Infarction Clinical Trial Pipeline Highlights, 2019" report has been added to ResearchAndMarkets.com's offering.
  • This report provides most up-to-date information on key pipeline products in the global Acute Myocardial Infarction market.
  • It covers emerging therapies for Acute Myocardial Infarction in active clinical development stages including early and late stage clinical trials.
  • The report provides Acute Myocardial Infarction pipeline products by clinical trial stages including both early and late stage development - phase 3 clinical trials, phase 2 clinical trials, phase 1 clinical trials, preclinical research, and discovery stage.

FDA Approves Initiation of STEMI DTU Pivotal Randomized Controlled Trial

Retrieved on: 
Thursday, May 2, 2019
Health, Biotechnology, Cardiology, Medical devices, Medicine, Circulatory system, Cardiovascular system, Medical emergencies, Aging-associated diseases, Acute pain, Myocardial infarction, RTT, Infarction, Abiomed, Remote ischemic conditioning, U.S. National STEMI Receiving Centers

Abiomed (NASDAQ: ABMD) announces that, on April 26, the FDA approved initiation of the ST-Elevation Myocardial Infarction Door-to-Unloading (STEMI DTU) Pivotal Randomized Controlled Trial.

Key Points: 
  • Abiomed (NASDAQ: ABMD) announces that, on April 26, the FDA approved initiation of the ST-Elevation Myocardial Infarction Door-to-Unloading (STEMI DTU) Pivotal Randomized Controlled Trial.
  • The prospective, multi-center, two-arm trial plans to enroll 668 patients undergoing treatment for a STEMI heart attack.
  • View the full release here: https://www.businesswire.com/news/home/20190502005270/en/
    The STEMI DTU safety and feasibility trial, when compared to the standard of care (reperfusion only) arm of the CRISP AMI trial demonstrates the potential to reduce infarct size in STEMI.
  • The STEMI DTU Pivotal Trial has the potential to improve the standard of care, slow the growing epidemic of heart failure and improve outcomes for millions of heart attack patients.